Industry Expertise ERBC is a long-standing CRO (50 years) in biotechnology research, specializing in translational preclinical models and services, which presents a strong opportunity to upsell advanced in vitro and in vivo capabilities to biopharmaceutical and chemical clients seeking de-risked R&D.

Translational Focus With emphasis on bridging preclinical and clinical research and offering regulatory pre-IND packages, ERBC can be positioned for premium consulting, study design optimization, and early regulatory support collaborations.

Animal Alternatives Prioritizing alternatives to animal testing signals demand for non-animal efficacy and safety models, enabling partnerships around humane, compliant, and innovative testing strategies that may attract clients pursuing 3Rs (reduce, refine, replace).

Engagement Footprint Active participation in major scientific events (EUROTOX, SOT, FELASA, Oncostart) and a visible analytics/CRM tech stack indicate a proactive sales channel with opportunities to engage attendees, showcase capabilities, and capture high-intent leads for preclinical and translational services.

Growth Signals Revenue is in the startup-to-mid tier range with 201-500 employees, suggesting capacity to scale collaborations, expand service lines, and pursue larger pharma partnerships while leveraging ongoing global events to widen client base.